Join to View Full Profile
VCU Massey Cancer Center1201 East Marshall Street, PO Box 980070McGlothlin Medical education Center 11th floor,Richmond, VA 23298
Phone+1 804-828-7999
Fax+1 804-828-5941
Dr. Poklepovic is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 2008 - 2011- Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2004 - 2007
University of South Florida College of MedicineClass of 2004
Certifications & Licensure
VA State Medical License 2007 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Start of enrollment: 2004 Sep 01
- Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Publications & Presentations
PubMed
- Durable disease control of adult-onset xanthogranuloma with time-limited mitogen-activated extracellular kinase inhibition: a case report.Hyun Lee, Ellie McCabe, Thuy Ho, Mark Mochel, Ariel Sindel
The British Journal of Dermatology. 2026-04-17 - 1 citationsLongitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin L Budde
Clinical Cancer Research. 2026-04-15 - Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, Andrew S Poklepovic, Varinder Kaur
Cancer Research Communications. 2026-04-01
Press Mentions
VCU Massey Offers First, Only TIL Therapy for Melanoma in VirginiaAugust 18th, 2025- VCU Health's Cancer Center Is the Only One in Virginia to Provide TIL Therapy for Advanced MelanomaAugust 18th, 2025
- On TrialApril 21st, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
